111 related articles for article (PubMed ID: 11723037)
1. Defining the optimal activated clotting times during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials.
Helft G; Beygui F; le Feuvre C; Metzger JP
Circulation; 2001 Nov; 104(22):E124. PubMed ID: 11723037
[No Abstract] [Full Text] [Related]
2. Optimal activated clotting time during percutaneous coronary intervention.
Hanratty CG; Ward M
Circulation; 2001 Oct; 104(15):E83-4. PubMed ID: 11591634
[No Abstract] [Full Text] [Related]
3. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
Marmur JD; Poludasu S; Feit A; Battala VR; Cavusoglu E
J Invasive Cardiol; 2008 Jul; 20(7):323-7. PubMed ID: 18599887
[TBL] [Abstract][Full Text] [Related]
4. Research review: use of activated clotting time to monitor heparin therapy in coronary patients.
Noureddine SN
Am J Crit Care; 1995 Jul; 4(4):272-7; quiz 278-9. PubMed ID: 7663590
[TBL] [Abstract][Full Text] [Related]
5. Increasing benefit, reducing risk: focusing on hemorrhagic complications in percutaneous coronary intervention.
Aguirre FV; Gill JB
J Invasive Cardiol; 2002 Apr; 14 Suppl B():48B-54B. PubMed ID: 11967390
[No Abstract] [Full Text] [Related]
6. Direct versus indirect thrombin inhibition in percutaneous coronary intervention.
Marmur JD
J Invasive Cardiol; 2002 Apr; 14 Suppl B():8B-18B. PubMed ID: 11967386
[No Abstract] [Full Text] [Related]
7. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
8. Venous activated clotting time after intra-arterial heparin: effect of site of administration and timing of sampling.
Kerensky RA; Azar GJ; Bertolet B; Hill JA; Kutcher MA
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):151-3. PubMed ID: 8808070
[TBL] [Abstract][Full Text] [Related]
9. The value of clinical wisdom in randomised studies, real-world registries and new hypotheses.
Bernardi G; Morocutti G; Spedicato L; Zanuttini D
J Cardiovasc Med (Hagerstown); 2007 May; 8(5):313-7. PubMed ID: 17443094
[No Abstract] [Full Text] [Related]
10. One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials.
Mercado N; Wijns W; Serruys PW; Sigwart U; Flather MD; Stables RH; O'Neill WW; Rodriguez A; Lemos PA; Hueb WA; Gersh BJ; Booth J; Boersma E
J Thorac Cardiovasc Surg; 2005 Aug; 130(2):512-9. PubMed ID: 16077421
[TBL] [Abstract][Full Text] [Related]
11. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
Dumaine R; Borentain M; Bertel O; Bode C; Gallo R; White HD; Collet JP; Steinhubl SR; Montalescot G
Arch Intern Med; 2007 Dec; 167(22):2423-30. PubMed ID: 18071163
[TBL] [Abstract][Full Text] [Related]
12. Transferring patients with ST-segment elevation myocardial infarction for mechanical reperfusion: a meta-regression analysis of randomized trials.
De Luca G; Biondi-Zoccai G; Marino P
Ann Emerg Med; 2008 Dec; 52(6):665-76. PubMed ID: 19027496
[TBL] [Abstract][Full Text] [Related]
13. The truth about activated clotting time measurements.
Bittl JA
Catheter Cardiovasc Interv; 2005 Jul; 65(3):338-9. PubMed ID: 15864807
[No Abstract] [Full Text] [Related]
14. Monitoring the effect of heparin bolus during percutaneous coronary angioplasty (PTCA): assessment of three bedside coagulation monitors.
Hézard N; Metz D; Potron G; Nazeyrollas P; Maes D; Droulle C; Mulpas MC; Elaerts J; Nguyen P
Thromb Haemost; 1998 Nov; 80(5):865-6. PubMed ID: 9843190
[No Abstract] [Full Text] [Related]
15. Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty.
Al Suwaidi J; Holmes DR; Salam AM; Lennon R; Berger PB
Am Heart J; 2004 May; 147(5):815-22. PubMed ID: 15131536
[TBL] [Abstract][Full Text] [Related]
16. [Activated coagulation time in the evaluation of anticoagulation with heparin in peripheral vascular surgery].
Brandi LS; Nannoni L; Carmellini M; Ferrari M; Grana M; D'Elia F; Parra PF; Mosca F
Minerva Cardioangiol; 1986 Apr; 34(4):273-7. PubMed ID: 3725034
[No Abstract] [Full Text] [Related]
17. Letter of comment on "Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial" (Am Heart J 2006;152:887.e9-14).
Vydt T; Agostoni P
Am Heart J; 2007 May; 153(5):e25; author reply e27. PubMed ID: 17452140
[No Abstract] [Full Text] [Related]
18. Analyzing randomized dose finding studies with a primary and a secondary endpoint.
Hothorn LA; Wassmer G
J Biopharm Stat; 2003 May; 13(2):301-5. PubMed ID: 12729396
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial of topical hemostasis pad use for achieving vascular hemostasis following percutaneous coronary intervention.
Nguyen N; Hasan S; Caufield L; Ling FS; Narins CR
Catheter Cardiovasc Interv; 2007 May; 69(6):801-7. PubMed ID: 17262862
[TBL] [Abstract][Full Text] [Related]
20. Can enoxaparin safely replace unfractionated heparin during coronary intervention in acute coronary syndromes?
Wolak A; Ayzenberg Y; Cafri C; Gilutz H; Ilia R; Zahger D
Int J Cardiol; 2004 Aug; 96(2):151-5. PubMed ID: 15262028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
